Labile iron in cells and body fluids: physiology, pathology, and pharmacology
Open Access
- 13 March 2014
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 5, 45
Abstract
In living systems iron appears predominantly associated with proteins, but can also be detected in forms referred as labile iron, which denotes the combined redox properties of iron and its amenability to exchange between ligands, including chelators. The labile cell iron (LCI) composition varies with metal concentration and substances with chelating groups but also with pH and the redox potential. Although physiologically in the lower µM range, LCI plays a key role in cell iron economy as cross-roads of metabolic pathways. LCI levels are continually regulated by an iron-responsive machinery that balances iron uptake versus deposition into ferritin. However, LCI rises aberrantly in some cell types due to faulty cell utilization pathways or infiltration by pathological iron forms that are found in hemosiderotic plasma. As LCI attains pathological levels, it can catalyze reactive O species (ROS) formation that, at particular threshold, can surpass cellular anti-oxidant capacities and seriously damage its constituents. While in normal plasma and interstitial fluids, virtually all iron is securely carried by circulating transferrin (that renders iron essentially non-labile), in systemic iron overload (IO), the total plasma iron binding capacity is often surpassed by a massive iron influx from hyperabsorptive gut or from erythrocyte overburdened spleen and/or liver. As plasma transferrin approaches iron saturation, labile plasma iron (LPI) emerges in forms that can infiltrate cells by unregulated routes and raise LCI to toxic levels. Despite the limited knowledge available on LPI speciation in different types and degrees of iron overload, LPI measurements can be and are in fact used for identifying systemic IO and for initiating/adjusting chelation regimens to attain full-day LPI protection. A recent application of labile iron assay is the detection of labile components in iv iron formulations per se as well as in plasma (LPI) following parenteral iron administrationKeywords
This publication has 71 references indexed in Scilit:
- Non-Transferrin-Bound Iron (NTBI) Uptake by T Lymphocytes: Evidence for the Selective Acquisition of Oligomeric Ferric Citrate SpeciesPLOS ONE, 2013
- Biogenesis of iron-sulfur clusters in mammalian cells: new insights and relevance to human diseaseDisease Models & Mechanisms, 2012
- Rescuing iron‐overloaded macrophages by conservative relocation of the accumulated metalBritish Journal of Pharmacology, 2010
- A Mammalian Siderophore Synthesized by an Enzyme with a Bacterial Homolog Involved in Enterobactin ProductionCell, 2010
- The role of iron in mitochondrial functionBiochimica et Biophysica Acta (BBA) - General Subjects, 2009
- Reduction in labile plasma iron during treatment with deferasirox, a once‐daily oral iron chelator, in heavily iron‐overloaded patients with β‐thalassaemiaEuropean Journal of Haematology, 2009
- A Cytosolic Iron Chaperone That Delivers Iron to FerritinScience, 2008
- Iron-regulatory proteins: molecular biology and pathophysiological implicationsExpert Reviews in Molecular Medicine, 2007
- Zip14 (Slc39a14) mediates non-transferrin-bound iron uptake into cellsProceedings of the National Academy of Sciences, 2006
- The Chelatable Iron Pool in Living Cells: A Methodically Defined QuantityBiological Chemistry, 2002